Trials / Completed
CompletedNCT00736593
A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.
A Phase 1 Randomized, Prospective, Within-Subject, Double-Blind, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Full-Thickness Punch Wounds
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- OcuNexus Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
Nexagon™ is a novel compound that promotes wound healing by temporarily disrupting cellular communication at the wound site, thereby promoting accelerated healing, reducing inflammation and pain. This randomized double-blind study will assess the safety, tolerability and clinical effect of Nexagon™ when applied to skin wounds created by punch biopsy in healthy volunteers. 43 healthy, fair-skinned males and females between ages 18-40 will be enrolled. Subjects will be reviewed again at 3 months and 9 months for follow-up safety assessments and wound appearance evaluation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nexagon™ or Nexagon™ vehicle |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-01-01
- Completion
- 2009-04-01
- First posted
- 2008-08-18
- Last updated
- 2009-04-27
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT00736593. Inclusion in this directory is not an endorsement.